Search Clinical Trials
589,087 trials
ID
Status
Phase
Title
Sponsor
NCT07643818
Intravenous Iron to Improve Symptoms, Quality of Life and Exercise Capacity in HFpEF With Iron DeficiencyGovernment of JerseyNot Yet RecruitingPhase 2
NCT07643818Not Yet Recruiting
Phase 2
Intravenous Iron to Improve Symptoms, Quality of Life and Exercise Capacity in H...Government of Jersey
NCT07645924
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of MigraineKallyope Inc.Not Yet RecruitingPhase 3
NCT07645924Not Yet Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute T...Kallyope Inc.
NCT07644507
Role of Intraoperative Computed Tomography in Assessment of Spine Instability in Lumbar Degenerative Disease4th Military Clinical Hospital with Polyclinic, PolandNot Yet Recruiting
NCT07644507Not Yet Recruiting
—
Role of Intraoperative Computed Tomography in Assessment of Spine Instability in...4th Military Clinical Hos...
NCT07645222
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLCHansoh BioMedical R&D CompanyNot Yet RecruitingPhase 1
NCT07645222Not Yet Recruiting
Phase 1
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLCHansoh BioMedical R&D Com...
NCT07644676
The Impact of Adhesion Strategy on the Clinical Performance Of Indirect Dental RestorationsMalmö UniversityEnrolling By InvitationNot Applicable
NCT07644676Enrolling By Invitation
Not Applicable
The Impact of Adhesion Strategy on the Clinical Performance Of Indirect Dental R...Malmö University
NCT07646353
First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy AdultsGlaxoSmithKlineNot Yet RecruitingPhase 1
NCT07646353Not Yet Recruiting
Phase 1
First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in H...GlaxoSmithKline
NCT07646080
Exploratory Study on Toripalimab and Anlotinib Combined With Standard Chemotherapy for Refractory Dermatofibrosarcoma ProtuberansYanjie Zhang, MDNot Yet RecruitingPhase 2
NCT07646080Not Yet Recruiting
Phase 2
Exploratory Study on Toripalimab and Anlotinib Combined With Standard Chemothera...Yanjie Zhang, MD
NCT07645547
Prophylactic Use of ciNPWT in Gynecologic LaparotomyUniversity Hospital Hradec KraloveNot Yet RecruitingNot Applicable
NCT07645547Not Yet Recruiting
Not Applicable
Prophylactic Use of ciNPWT in Gynecologic LaparotomyUniversity Hospital Hrade...
NCT07643935
Prognostic Value of 177Lutetium-PSMA Single Photon Emission Tomography and Timing of ResponseCentral Hospital, Nancy, FranceNot Yet Recruiting
NCT07643935Not Yet Recruiting
—
Prognostic Value of 177Lutetium-PSMA Single Photon Emission Tomography and Timin...Central Hospital, Nancy,...
NCT07646327
Sustained Natural Apophyseal Glides With and Without Facilitated Positional Release Technique in Cervicogenic DizzinessRiphah International UniversityNot Yet RecruitingNot Applicable
NCT07646327Not Yet Recruiting
Not Applicable
Sustained Natural Apophyseal Glides With and Without Facilitated Positional Rele...Riphah International Univ...
NCT07645664
Scar Management Through Serial CastingCentre hospitalier de l'Université de Montréal (CHUM)Not Yet RecruitingNot Applicable
NCT07645664Not Yet Recruiting
Not Applicable
Scar Management Through Serial CastingCentre hospitalier de l'U...
NCT07646262
Gluten-Free vs Mediterranean Diet in Rheumatoid ArthritisHasan Kalyoncu UniversityRecruitingNot Applicable
NCT07646262Recruiting
Not Applicable
Gluten-Free vs Mediterranean Diet in Rheumatoid ArthritisHasan Kalyoncu University
NCT07645534
Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90 mg, Under Fasting and Fed Conditions.Valenta Pharm JSCRecruitingPhase 1
NCT07645534Recruiting
Phase 1
Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta...Valenta Pharm JSC
NCT07646054
Digital Lifestyle Coaching for Alzheimer's Disease Prevention in APOE4 Carriers23andMe, Inc.Not Yet RecruitingNot Applicable
NCT07646054Not Yet Recruiting
Not Applicable
Digital Lifestyle Coaching for Alzheimer's Disease Prevention in APOE4 Carriers23andMe, Inc.
NCT07645950
Effect of the MIROKI Companion Robot on Anxiety in Pediatric RadiotherapyInstitut du Cancer de Montpellier - Val d'AurelleNot Yet Recruiting
NCT07645950Not Yet Recruiting
—
Effect of the MIROKI Companion Robot on Anxiety in Pediatric RadiotherapyInstitut du Cancer de Mon...
NCT07645105
Body Weight Reduction and Metabolic/Biochemical Parameters in Overweight or ObesityMedical University of SilesiaCompleted
NCT07645105Completed
—
Body Weight Reduction and Metabolic/Biochemical Parameters in Overweight or Obes...Medical University of Sil...
NCT07644767
Adjunctive Oral KET-AD Capsules in Treatment Resistant Bipolar DepressionNeurocentrx Pharma Pty LtdNot Yet RecruitingPhase 2
NCT07644767Not Yet Recruiting
Phase 2
Adjunctive Oral KET-AD Capsules in Treatment Resistant Bipolar DepressionNeurocentrx Pharma Pty Lt...
NCT07643831
Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast CancerGenentech, Inc.Unknown
NCT07643831Unknown
—
Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2-...Genentech, Inc.
NCT07646366
Effects of the Egoscue Exercises With and Without Mwm Among Patients With Knee OsteoarthritisRiphah International UniversityNot Yet RecruitingNot Applicable
NCT07646366Not Yet Recruiting
Not Applicable
Effects of the Egoscue Exercises With and Without Mwm Among Patients With Knee O...Riphah International Univ...
NCT07645625
Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical CancerUniversity Medical Center GroningenRecruitingPhase 4
NCT07645625Recruiting
Phase 4
Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical CancerUniversity Medical Center...
Result Breakdown
Not yet recruiting14 (70%)
Recruiting3 (15%)
Enrolling by invitation1 (5%)
Completed1 (5%)
Unknown1 (5%)
not_applicable7 (35%)
Not Specified5 (25%)
Phase 23 (15%)
Phase 13 (15%)
Phase 31 (5%)
Phase 41 (5%)